Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders Fourth U.S. FDA Approval for Ultragenyx in the Past Three Years – All for Rare Diseases which Previously Had No Approved Therapies Ultragenyx to Host Conference Call Today at 4:00 pm [...]

By |2023-02-13T11:18:36-05:00February 13th, 2023|

INFORM Conference Explores Future of Disorders of Fatty Acid Oxidation

INFORM Conference Explores Future of Disorders of Fatty Acid Oxidation International Network for Fatty Acid Oxidation Research and Management showcased advancements, next-gen researchers Global experts, practitioners, researchers and family members gathered this fall for the ninth meeting of the International Network for Fatty Acid Oxidation Research and Management. Held in [...]

By |2022-11-29T09:11:52-05:00November 29th, 2022|

The Role of Carnitine in Metabolic Myopathies (MM)

How is CPT2 Diagnosed? Most people never think about the adverse impacts of dieting or skipping a meal on a busy day. We assume that this is a normal function of the body that can be handled by the body. Under normal circumstances, this is true as the body can [...]

By |2022-11-16T13:41:29-05:00November 16th, 2022|

LCFAOD Symptoms Linked to Alterations in Complex Lipids

LCFAOD Symptoms Linked to Alterations in Complex Lipids. Accumulated altered versions of complex lipids sphingomyelins, ceramides, and cardiolipin are likely responsible for LCFAO symptoms according to a study. A recently published hypothesis article by the International Journal of Molecular Medicine indicates that retinopathy and neurodegenerative symptoms associated with patients that [...]

By |2022-10-24T10:23:53-04:00October 24th, 2022|

Efficacy of a Diet Supplemented With Triheptanoin Proven Greater Than IMB-203 in Treating VLCAD Deficiency

Efficacy of a Diet Supplemented With Triheptanoin Proven Greater Than IMB-203 in Treating VLCAD Deficiency Triheptanoin (C7) has shown effectiveness in treating CoA dehydrogenase VLCAD deficiency, a type of LCFAOD. It has also shown to have greater efficacy than IMB-203. The study found that C7 reduced hepatic steatosis, whereas IMB-203 [...]

By |2022-09-23T11:31:03-04:00September 23rd, 2022|
Go to Top